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Abstract
Background: Bone destruction is a feature of multiple myeloma, characterised by osteolytic bone destruction due
to increased osteoclast activity and suppressed or absent osteoblast activity. Almost all multiple myeloma patients
develop osteolytic bone lesions associated with severe and debilitating bone pain, pathologic fractures, hypercalcemia,
and spinal cord compression, as well as increased mortality. Biomarkers of bone remodelling are used to identify
disease characteristics that can help select the optimal management of patients. However, more accurate biomarkers
are needed to effectively mirror the dynamics of bone disease activity.
Results: A label-free mass spectrometry-based strategy was employed for discovery phase analysis of fractionated
patient serum samples associated with no or high bone disease. A number of proteins were identified which were
statistically significantly correlated with bone disease, including enzymes, extracellular matrix glycoproteins, and
components of the complement system.
Conclusions: Enzyme-linked immunosorbent assay of complement C4 and serum paraoxonase/arylesterase 1
indicated that these proteins were associated with high bone disease in a larger independent cohort of patient
samples. These biomolecules may therefore be clinically useful in assessing the extent of bone disease.
Keywords: Biomarkers, Bone disease, C4, Mass spectrometry, PON1, Proteomics
Background
Osteolytic bone disease is a common complication of
multiple myeloma, with 70% of patients having bone
lesions at diagnosis [1]. Bone-destroying osteoclasts are
more active in myeloma than bone-forming osteoblasts,
ultimately leading to bone destruction. These lesions
weaken bone, causing pain, spinal cord compression,
hypercalcemia, and increased risk of fractures [2].
Moreover, bone repair appears to be inhibited at sites
of osteolytic lesions. The standard method for detecting
bone lesions is through a radiographic (x-ray) skeletal
survey, which is relatively insensitive. Studies have demon-
strated that whole-body computerised tomography (CT)
scans are better than x-rays for detecting bone lesions;
however, concerns about radiation dose exist [3,4]. While
radiological evaluation of the bony skeleton is important
for detecting bone disease in MM patients, imaging
studies only provide cross-sectional information reflecting
bone dynamics. Even the most sensitive imaging tech-
niques only detect established cortical bone destruction.
Biomolecules, measured in biofluids such as blood or
urine provide for longitudinal information concerning
bone disease. Indeed MM is characterised by repeated
relapses, with increasing destruction at relapse [5]; sensitive
markers of osteoclast destruction therefore may detect
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ventative intervention. Specifically, ELISA-based bone
marker assays would offer a low cost, widely accessible,
non-radiation-based method of longitudinally monitor-
ing dynamic changes in osteoclast activity [6]. Current
bone biomolecules can be divided into two categories,
collagen fragments released from the bone matrix
during resorption (degradation); and enzymes released
from either osteoblasts or osteoclasts. Biomarkers reflect-
ing osteoclast-mediated degradation of collagen include
N-terminal cross-linking telopeptide of type-1 collagen
(NTX), C-terminal cross-linking telopeptide of type-1
collagen (CTX), C-terminal cross-linking telopeptide of
type-1 collagen generated by metalloproteinase (ICTP), and
deoxypyridinoline (DPD). Procollagen type-1 N-propeptide
(PINP) and procollagen type-1 C-propeptide (PICP) signify
new bone formation [7,8]. Tartrate-resistant acid phosphat-
ase isotype 5b (TRACP-5b) is an enzyme used as a marker
of osteoclast number and activity, while bone-specific
alkaline phosphatase (BALP) and osteocalcin (OC), pro-
duced by osteoblasts, are used as markers of osteoblast
number and activity [9]. Receptor activator of nuclear
factor-kappa B ligand (RANKL) and Osteoprotegerin
(OPG) are also important markers of bone turnover.
RANKL increases osteoclast activity and is regulated by
OPG, the soluble decoy receptor for RANKL, which
serves as an inhibitor of RANKL activity. The RANKL/
OPG ratio therefore can serve as an index of osteoclas-
togenic activity [10,11]. Although these biochemical
markers of bone destruction and formation are useful
measurements in assessing the extent of myeloma bone
disease, no individual marker has proved to be com-
pletely effective at mirroring the dynamics of bone
disease activity [6].
In this investigation, we applied a discovery proteomics-
based approach to identify novel circulating biomolecules
that accurately correlate with degree of bone disease in
MM patients.
Results
Patient data
Table 1 shows clinical data for the 111 patient samples (D -
samples used in the discovery phase; V - samples used in
the validation phase) used in this study including 41
patients with no bone disease, 49 patients with high bone
disease, and 21 patients with MGUS/SMM (Monoclo-
nal gammopathy of undetermined significance (MGUS) &
smoldering multiple myeloma (SMM)). A total of 10 patient
serum samples with no bone disease and 10 patient serum
samples with high bone disease were used during the dis-
covery phase analysis. The remaining samples, including
MGUS and SMM were included in the validation analysis
of C4, B100 and PON1.
Label-free mass spectrometry
In total 159 proteins were positively identified in the
Proteominer enriched serum samples using Progenesis
LC-MS to align these runs, of which 24 differentially
expressed proteins are included in the protein table
(Table 2). Label-free mass spectrometry is a powerful
and widely-used technique for identifying and quantifying
relative changes in complex protein samples, including
serum. Serum presents a significant challenge in proteo-
mics research, displaying a huge dynamic range which
exceeds ten orders of magnitude. To help overcome this
problem, ProteoMiner™ pre-fractionation was employed to
compress the dynamic range and facilitate the discovery of
disease-related biomolecules found in the serum prote-
ome. Of the proteins identified during the discovery phase,
Complement C4-A (C4A, p =0.05, 2.8-fold ₑ high bone
disease), Apolipoprotein B-100 (APOB, p =0.04, 2.2-fold ₓ
high bone disease) and Serum paraoxonase/arylesterase
(PON1, p =0.02, 1.6-fold ₑ high bone disease) were
selected for further analysis in a larger cohort of patient
samples. Previous work by our group has demonstrated
that serum levels of C4, B100 and PON1 are abnormal
in patients found to be responders/non-responders to
MM therapies, including Thalidomide and Bortezomib
(see Additional file 1: Table S1), therefore it would be
of interest to see if any correlation existed with bone
disease, especially as these proteins appeared in the
discovery phase protein list.
STRING analysis
Protein associations and networks from the list of
proteins with significantly changed abundance levels
between no bone disease and high bone disease MM
patient serum samples were analysed using STRING
(Search Tool for the Retrieval of Interacting Genes), a
database of known and predicted protein-protein inter-
actions [12]. It generates a network of interactions from
a variety of sources, including different interaction
databases, text mining, genetic interactions, and shared
pathway interactions. The evidence view is shown in
Figure 1A, and the action view is shown in Figure 1B.
The colour-coded legend for the evidence view shows
the type of the interactions between proteins including
databases and text mining. The action view shows the
type of evidence that supports the interaction, such as
binding and inhibition. A central cluster of interacting
proteins is evident comprised of Alpha-1-antitrypsin
(SERPINA1 ₓ), Albumin (ALB ₓ), Plasminogen (PLG ₓ),
Kininogen 1 (KNG1 ₓ), Coagulation factor V (F5 ₓ),
Fibronectin (FN1 ₑ), Alpha-2-macroglobulin (A2M ₓ)a n d
Platelet factor 4 (PF4 ₓ). The majority of the proteins in
this cluster were found to be decreased in abundance in
high bone disease MM patient samples compared to no
bone disease, except for FN1.
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Patient
ID
No bone disease Bisphosphonate
tx (Y/N)
1 (D) PET: no focal myelomatous lesions Y
2 (D) SS: No lytic lesions. N
3 (D) SS: no lytic lesions. Diffuse osteopenia. N
4 (D) SS: no evidence of lytic bone lesions N
5 (D) SS: no lytic disease N
6 (D) SS: no focal lytic lesions. Y
7 (D) SS and MRI spine: no lytic lesions N
8 (D) SS: no lytic lesions Y
9 (D) Notes: no evidence of bone disease on SS. N
10 (D) SS: no bone disease N
11 (V) SS: no lytic lesions identified. N.
12 (V) SS: no lytic lesions. MRI spine:
no focal ltic lesions.
N
13 (V) SS: no lytic lesions. N
14 (V) SS: no bone disease N
15 (V) Notes: SS negative for lytic bone disease. N
16 (V) SS and MRI spine: no lytic disease N
17 (V) SS: no lytic lesions. N
18 (V) SS: no lytic lesions N
19 (V) SS (x2): negative metastatic bone series. n/a
20 (V) SS: no lytic lesions or vert #s N
21 (V) SS: no evidence of lytic disease N
22 (V) SS: no lytic lesions N
23 (V) SS: no lytic lesions Y
24 (V) SS: no lytic lesions N
25 (V) SS: no lytic lesions Y
26 (V) SS: no lytic lesions. N
27 (V) SS: no dominant lytic lesion seen. N
28 (V) SS: no findings related to myeloma. N
29 (V) Notes: no lytic lesions SS N
30 (V) Notes (x2): no myeloma bone disease on SS. N
31 (V) Notes: no evidence of lytic bone disease (SS). Y
32 (V) SS: no evidence of lytic bone disease. Y
33 (V) SS and CT abdo/pelvis: no lytic lesions Y
34 (V) SS (x2): no lytic bone diesase. Y
35 (V) SS: no focal lucencies suggestive of myeloma. n/a
36 (V) SS: no lytic lesions N
37 (V) SS: no lytic lesions Y
38 (V) SS, CT spine and PET-CT: no lytic lesions. N
39 (V) SS: no lytic lesions N
40 (V) SS: no lytic disease Y
41 (V) SS: no lytic lesions Y
Table 1 Clinical data (Continued)
Patient
ID
High bone disease Bisphosphonate
tx (Y/N)
42 (D) Lytic lesions in hip on MRI, and in
thorax on CT.
N
43 (D) Multiple lytic lesions, skull, pelvis, femur (SS) Y
44 (D) MRI: widespread bone disease, including
extramedullary involvement.
Y
45 (D) SS: multiple lucencies skull, pelcis,
femora, compression #s spine.
n/a
46 (D) SS: diffuse lytic disease N
47 (D) SS: C2 lesion and femoral neck lesions. N
48 (D) SS: multiple involving skull, humeri, femora. Y
49 (D) SS: multiple lucencies in the skull,
and femoral lesion.
N
50 (D) Notes: Multiple lytic bone lesions Y
51 (D) SS: multiple lytic lesions throughout skeleton. Y
52 (V) SS: lucencies invol. Ribs,
scapulae, T/L spines.
N
53 (V) Notes: multiple bony lesions with
soft tissue extension.
n/a
54 (V) MRI: multiple spinal lesions Y
55 (V) Notes: extensive bone involvement. Y
56 (V) SS: lucencies of skull, humerus, femur, pelvis. N
57 (V) SS: lesions of skull, ribs, humera, femur. N
58 (V) SS: multiple lucencies femurs, humeri, skull Y
59 (V) SS and MRI: skull, clavicle, vertebral lesions. Y
60 (V) Vertebral, femoral, extramedullary
(lung) lesions.
N
61 (V) SS: skull, humeri, vert lesions. Y
62 (V) PET-CT: increased uptake left ilial and
T12 vert, rib #s
N
63 (V) MRI: multiple compression #s
spine, sacral lesions
Y
64 (V) SS: multiple lucencies, skull, humeri, femurs. n/a
65 (V) SS: femurs, pelvis, skull luc, compressn # T9 Y
66 (V) CT: lumbar spine, rib, pelvis, sternal lesions Y
67 (V) MRI: multiple vertebral lesions Y
68 (V) SS: lesions skull, pelvis, femora. Y
69 (V) SS: skull, humrea, vert lesions n/a
70 (V) Notes: scapular, pelvic and hip lesions. Y
71 (V) SS: skull, vert, humeri lucencies N
72 (V) SS/MRI: multiple lesions pelvis and lt humerus. Y
73 (V) SS/MRIs: lumbar, thoracic and sacral lesions. Y
74 (V) SS/PET: skull lesions and sternal plasmacytoma N
75 (V) SS: lucencies femora, skull, humerus. N
76 (V) SS: diffuse myel. involve. (skull, hum,
fem, t spine, skull).
Y
77 (V) Notes: lucencies C/T spine and scapula. N
78 (V) Y
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(AUC) analysis
Box and whisker plots were constructed to display infor-
mation about the range, the median and the quartiles for
Complement C4 (Figure 2A) and Serum paraoxonase/
arylesterase (Figure 2B) based on ELISA results from an
independent validation cohort of patient samples, includ-
ing monoclonal gammopathy of undetermined signifi-
cance (MGUS), smoldering multiple myeloma (SMM),
MM patients with no bone disease and MM patients
with bone disease. B100 was not statistically signifi-
cantly correlated with bone disease in the independent
sample set. C4 and PON1 were found to be significant,
with overall concentration increasing from MGUS/
SMM (C4: 176 ug/ml, PON1: 204 ug/ml) to no bone
disease (C4: 248 ug/ml, PON1: 301 ug/ml) to high bone
d i s e a s e( C 4 :2 7 2u g / m l ,P O N 1 :5 0 2u g / m l ) .C 4w a s
found to be statistically correlated in 3 comparisons:
p =0.02 (MGUS/SMM v no bone disease), p =0.001
(MGUS/SMM v high bone disease) and p =0.05 (no bone
disease v high bone disease). PON1 was significantly
associated in 2 comparisons: p =0.008 (MGUS/SMM v
high bone disease) and p =0.01 (no bone disease v high
bone disease). Figure 2 summarises information on the
median, minimum and maximum values for C4 and
PON1. Statistical analysis was also completed compar-
ing patients who were receiving bisphosphonate treat-
ment (tx) versus no treatment at the time the sample
was obtained (Table 1) for C4 and PON1. None of these
comparisons were found to be statistically significant
(data not shown).
Receiver operating characteristic (ROC) curve were
constructed with the area under the ROC curve (AUC)
calculated to indicate the performance of both C4 and
PON1 at distinguishing pre-malignant myeloma v no
bone disease, pre-malignant myeloma v high bone dis-
ease and no bone disease v high bone disease (Figure 2).
The most significant AUC-values were found when
comparing pre-malignant myeloma to high bone disease
for both C4 and PON1, with values of 0.747 and 0.682
respectively. AUC-values were also determined for the
combination of C4 and PON1 using logistic regression
analysis to discriminate between the different groups,
with a value of 0.695 for pre-malignant myeloma v no
bone disease, 0.801 for pre-malignant myeloma v high
bone disease and 0.702 for no bone disease v high bone
disease. Similarly to the individual AUC-values, the most
significant value was found for the pre-malignant mye-
loma v high bone disease comparison (0.801).
Discussion
Protein analysis, specifically looking at serum proteins
found to have differences in abundance levels associated
with disease phenotype, in this case pre-malignant MM
Table 1 Clinical data (Continued)
Notes: destructive lesions L2 and
acetabulum.
79 (V) SS: compressn #s spine, lucencies skull,
femora, humeri.
Y
80 (V) PETCT: diffuse uptake spine, sternum,
femora.
N
81 (V) MRI: T7-9 lesions with cord compression N
82 (V) SS: lucencies femora, skull, humeri. Y
83 (V) SS: lucencies of skull, clavicles,
humera, T spine.
Y
84 (V) CT: 2 rib #s and compressn # T5 N
85 (V) CT: innumerable lesions within
axial and appendicular skeleton.
N
86 (V) SS: lucencies in vert, pelvis, humeri, femora. N
87 (V) SS: lesions in skull, ribs, T spine, humeri. Y
88 (V) SS: multiple lesions skull, pelvis,
and T12 compressn #.
n/a
89 (V) Notes: review of outside films
demonstrates extensive bony disease
N
90 (V) SS: Numerous lesions in skull and extremeties. N
Patient
ID
Pre-malignant myeloma Bisphosphonate
tx (Y/N)
91 (V) MGUS N
92 (V) MGUS N
93 (V) MGUS N
94 (V) MGUS N
95 (V) MGUS N
96 (V) MGUS N
97 (V) MGUS N
98 (V) MGUS N
99 (V) MGUS N
100 (V) SMM N
101 (V) SMM N
102 (V) SMM N
103 (V) SMM N
104 (V) SMM N
105 (V) SMM N
106 (V) SMM N
107 (V) SMM N
108 (V) SMM N
109 (V) SMM N
110 (V) SMM N
111 (V) SMM N
Clinical data for the 111 patient samples used in this study. 41 patients
diagnosed with no bone disease, 49 patients with high bone disease and 21
patients with monoclonal gammopathy of undetermined significance (MGUS)
or smoldering multiple myeloma (SMM). Samples are labeled with (D) for
discovery and (V) for validation, indicating the phase in which they were used.
Information on whether the patients were on bisphosphonate treatment (tx)
at the time the sample was taken is included (Y = yes, N= no).
n/a= not available.
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high bone disease, can help delineate the complex mech-
anisms of bone biology and also provide clinicians with
a suite of biomarkers to aid in the management of MM
patients. In this investigation, ProteoMiner fractionated
patient samples were analysed using a bottom-up
(peptide level) label-free mass spectrometric proteomic
strategy for biomarker discovery. A number of proteins
found to be statistically significant, correlating with bone
disease, were identified including enzymes, extracellular
matrix glycoproteins, and members of the complement
system. C4, B100 and PON1 were selected for further
analysis in a larger independent cohort of patient sam-
ples (based on previous unpublished findings), with both
C4 and PON1 confirmed to be significantly associated
with bone disease.
MM is characterised by repeated relapses ultimately cul-
minating in fatal refractory disease. The rate of MM bone
disease increases with progression of disease. While CT
and MRI scans have improved resolution and sensitivity
for detecting bone disease, there is a need for more sensi-
tive biochemical markers that will detect sub-clinical bone
disease, [13]. Protein markers of bone turnover provide
clinically useful supportive information on bone homeo-
stasis by measuring enzymes, cytokines and collagen
breakdown products released during bone formation and
of degradation products produced during bone resorption.
A range of biochemical bone markers are available that
allow a specific and sensitive evaluation of the rate of bone
formation and bone resorption of the skeleton; however,
none of the currently known biomarkers are used in clin-
ical practice, and more robust and sensitive biomarkers
are needed to both monitor bone turnover and aid in
managing patients with bone disease [14]. Due to expense,
access to radiology, and radiation exposure, radiology
techniques are used in the setting of rising paraprotein or
new symptomatology. The majority of patients will already
have new bone lesions and/or fracture [15]. Moreover, there
Table 2 Protein list
Gene symbol Protein identification Measured peptides MASCOT score BH adjusted p-value Fold change
VTN Vitronectin 6 391 0.02 −2.7
KNG1 Kininogen-1 2 115 0.02 1.4
THBS1 Thrombospondin-1 5 343 0.02 3.0
PON1 Serum paraoxonase/arylesterase 1 3 166 0.02 −1.6
PLG Plasminogen 8 545 0.02 1.5
F5 Coagulation factor V 4 210 0.03 1.8
F2 Prothrombin 10 722 0.03 1.8
AMBP Protein AMBP 2 124 0.04 2.4
APOB Apolipoprotein B-100 4 1640 0.04 2.2
PROS1 Vitamin K-dependent protein S 3 198 0.04 2.0
CFHR1 Complement factor H-related protein 1 2 171 0.04 1.8
TTR Transthyretin 2 163 0.04 −2.2
PF4 Platelet factor 4 2 186 0.04 1.4
SERPINA1 Alpha-1-antitrypsin 3 247 0.04 2.4
AHSG Alpha-2-HS-glycoprotein 5 454 0.04 3.5
FN1 Fibronectin 7 567 0.05 −4.5
HRG Histidine-rich glycoprotein 2 97 0.05 3.0
TF Serotransferrin 2 195 0.05 3.2
IGHG2 Ig gamma-2 chain C region 3 214 0.05 2.0
ALB Serum albumin 4 311 0.05 3.6
C1S Complement C1s subcomponent 2 112 0.05 2.6
IGHM Ig mu chain C region 4 265 0.05 −2.7
C4A Complement C4-A 5 310 0.05 −2.8
A2M Alpha-2-macroglobulin 2 157 0.05 3.3
List of differentially expressed proteins comparing no bone disease to high bone disease. The table includes information on gene symbol, protein identification,
measured peptides (used for quantitation), confidence score (MASCOT), Benjamini-Hochberg adjusted p-value and fold-change (- indicates a protein is decreased
in abundance in no bone disease compared to high bone disease, all other proteins are increased in abundance in no bone disease compared to high bone
disease). A total of 10 patient serum samples with no bone disease and 10 patient serum samples with high bone disease were used during the discovery
phase analysis.
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http://www.biomedcentral.com/1471-2164/15/904Figure 1 STRING analysis of 24 differentially expressed proteins listed in Table 2. The STRING program generates functional protein
association networks. (A) Evidence view; uses different-coloured lines to depict the type of evidence that supports each interaction. (B) Action
view; uses different-coloured lines to depict the types of interaction between proteins.
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http://www.biomedcentral.com/1471-2164/15/904Figure 2 Box and whisker plots and ROC curves with associated AUC-values for Complement C4 (A) and PON1 - Serum paraoxonase/
arylesterase (B) in patient samples (Pre-malignant Myeloma: MGUS/SMM, MM: No Bone Disease and MM: High Bone Disease). The box
and whisker plots display information on the range, median and quartiles. A total of 31 patient samples with no bone disease, 39 patient samples
with high bone disease and 21 patient samples with MGUS/SMM were screened by ELISA.
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in patients receiving bisphosphonate therapy [16]. These
challenges reinforce the need for non-invasive, informative,
and sensitive bone markers that will allow for early detec-
tion of bone disease and preventative intervention.
It was observed that complement factor H-related pro-
tein 1 and complement C1s subcomponent were present
at lower concentrations in the patients with high bone
disease compared to no bone disease. The complement
system is made up of a series of about 25 proteins, two-
thirds of which circulate in the plasma while the remain-
der are present on cell and tissue surfaces. A recent
review discusses the link between the complement pro-
teins and their role in bone development and homeostasis,
specifically investigating their influence on osteoblast and
osteoclast activity [17]. The complex interplay between
these systems is still not fully understood but increasing
evidence points to the complement anaphylatoxins influ-
ence the migration of bone cells and the controlled inter-
actions between osteoblast and osteoclast. C4, as a major
protein of the classical cascade potentially has an import-
ant role in these important interactions. This system
works to “complement” the activity of antibodies in
destroying bacteria, either by facilitating phagocytosis or
by puncturing the bacterial cell membrane; however, re-
cent developments have shed some light on the role of the
complement system in bone formation and maintenance.
We for the first time found Complement C4-A to be
increased in the high bone disease patient cohort. In the
larger validation cohort, increasing levels of complement
C4 were determined when moving from MGUS/SMM to
no-bone disease to high-bone disease phenotypes. In-
creased C4 values have previously been associated with
systemic lupus erythematous, rheumatoid arthritis, severe
bacterial or viral infections, cancer, and myocardial infarc-
tion [18-20]. Zheng and co-workers reported increased
levels of complement C4 in MM patients, suggesting that
upregulation of complement components is due to defect-
ive activation [21].
Both Apolipoprotein B100 and PON1 were selected for
further analysis in a larger sample set. B100 was not found
to be significant in the validation cohort, but PON1 did
show a stepwise increase in concentration from MGUS/
SMM to high bone disease (as did complement C4). Serum
paraoxonase/arylesterase 1 (PON1) degrades chemicals
including several types of organophosphate pesticides and
pharmaceutical drugs in the body. PON1 also has antioxi-
dant properties, protecting both high- and low-density
lipoproteins from oxidation associated with changing
mineral content and decreased formation of bone [22].
Polymorphisms and abnormal enzymatic activity of PON1
have also been implicated in heart disease, osteoporosis,
atherosclerosis, and cancer [23-26]. Moreover, PON1
can directly suppress the macrophage pro-inflammatory
response [27]. The PON1 gene is activated by peroxi-
some proliferator-activated receptor γ (PPARγ), a mem-
ber of the ligand-activated nuclear receptor superfamily
[28]. Redox balance in bone cells is a key modulator of
normal functioning, and the increased levels of PON1
detected in patient serum samples in this study may
therefore represent a protective mechanism against the
effects of oxidative stress on bone formation associated
with osteoclastic resorption. Oxidative stress is involved in
the pathogenesis of bone diseases such as osteoporosis, in-
crease in osteoclasts activity and upregulation of osteoclast
differentiation. Therefore, it could be proposed that the
increased levels of PON1 are in response to this increased
stress, to facilitate the antioxidant bioscavenger of this
molecule and try to re-balance bone remodelling.
A number of other proteins were found to be signifi-
cantly correlated with different levels of bone disease.
Cells adhere to the extracellular matrix through inter-
action with adhesive extracellular matrix glycoproteins,
including vitronectin (VTN) and Fibronectin (FN1). VTN,
also known as S-protein, is a multi-functional plasma and
extracellular matrix protein with defined activity in cell
adhesion, thrombosis, complement activation, fibrinolysis,
inflammation, and platelet adhesion. Several groups have
shown the important role that vitronectin plays in the
development and regulation of bone structure [29-31].
FN1 is a multifunctional, extracellular matrix glycoprotein
composed of two disulfidebound polypeptides of molecu-
lar weight 220 kDa exhibiting structural and adhesive
properties in cell-associated fibrillar matrices. Similar to
VTN, FN1 is implicated in early stages of bone formation,
and continuous presence of FN1 is required for maintain-
ing the integrity of the bone matrix [32-34]. Our discovery
phase results demonstrate a significant elevation in the
concentrations of bothVTN and FN1 in high bone disease
compared to no bone disease patient samples, suggesting
that these proteins are released into the circulation due to
increased bone resorption related to stimulation of osteo-
clast formation and activity. These results compare with
the distribution of type I collagen fragments after osteo-
clastic degradation, including NTX and CTX, markers
which are used for the early diagnosis of bone lesions [35].
Finally, bisphosphonate treatment at the time of sample
collection was an important consideration with respect
to the potential impact that this treatment would have
on expression of the candidate biomarkers. Statistical
analysis showed that bisphosphonate treatment did not
significantly impact C4 and PON1 levels, suggesting
their potential utility in patients receiving bisphospho-
nate therapy, in combination with existing biochemical
tests and MRI/CTscanning.
From the information in the supplementary table, both
C4A and PON1 were found to be elevated in patients
responding to treatment, while in this study, both were
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ease group compared to both the pre-malignant myeloma
and no bone disease cohorts. Therefore, a direct link
between disease burden and the levels of these candidate
biomarkers is not obvious and may indicate a more de-
fined role in measuring bone disease. A limitation of this
investigation is the number of groups analysed in the val-
idation phase. Pre-malignant myeloma and both no/high
bone disease cohorts were examined. Ideally this would be
expanded out to include multiple myeloma disease stages
with associated bone disease information. Also, the main
utility of these proposed biomarkers would be in tracking
individual patients during the course of their disease, in-
vestigate how the abundance of these biomarkers changes
in relation to disease state and how this information could
be useful in patient management.
Conclusion
In summary, this study identifies novel candidate bio-
markers associated with bone disease in MM patients.
These novel biomarkers are currently being further evalu-
ated in prospective studies of MM bone disease to assess
their clinical utility.
Methods
Patients selection and sample collection
The participating subjects, attending the Jerome Lipper
Multiple Myeloma Center and LeBow Institute for
Myeloma Therapeutics, Dana-Farber Cancer Institute,
Harvard Medical School, Boston, MA, US, and the
Mater Hospital, Dublin, Ireland, gave written informed
consent in accordance with the Declaration of Helsinki
that was approved by the Institutional Review Board
(Dana-Farber Cancer Institute) and the Mater Hospital
ethics committee. The samples were collected according
to standard phlebotomy procedures from consented
patients. 10 ml of blood was collected into additive free
(serum) blood tubes and was allowed to clot for 30 min
to 1 hr at room temperature. The serum was denuded
by pipette from the clot and poured into a clean tube. The
tubes were centrifuged at 1000 × g for 30 min at 4°C.
Serum was aliquoted in the cryovial tubes, labeled and
stored at −80°C until time of analysis. The time from
sample procurement to storage at −80°C was less than
3 hr. Each serum sample underwent not more than three
freeze/thaw cycles prior to analysis.
ProteoMiner™ fractionation
Serum protein equalization was performed using
ProteoMiner™ enrichment kit according to the manufac-
turer procedure. In summary, the storage solution was
first washed out from the spin column containing
100 μL of peptide beads with deionised water. There-
after, the column was washed with the 10 mM NaH2PO4,
150 mM NaCl, pH 7.4 solution provided with the kit.
When the spin column was ready for sample binding,
1 mL of centrifuged serum sample was added to the col-
umn and equilibrated at room temperature for 2 hr. The
unbound proteins were removed with the wash buffer and
the captured proteins were eluted by 3×100 μLo f8M
urea containing 2% CHAPS dissolved in 5% acetic acid.
Following vortexing, sonication and centrifugation, the
protein concentration of no bone disease and high bone
disease patient samples was determined. Volumes of pro-
tein suspensions were equalized using label-free solubilisa-
tion buffer and then reduced for 30 min with 10 mM DTT
and alkylated for 20 min in the dark with 25 mM iodoace-
tamide in 50 mM ammonium bicarbonate. The proteolytic
digestion of proteins was carried out in 2 steps. Firstly,
digestion was performed with sequencing grade Lys-C at a
ratio of 1:100 (protease/protein) for 4 hr at 37°C, followed
by diluted with 4 times the initial sample volume in 50
mM ammonium bicarbonate. Secondly, further digestion
was based on incubation with sequencing grade trypsin at
a ratio of 1:25 (protease/protein) overnight at 37°C. The
protease-treated serum protein suspensions were diluted
3:1 (v/v) with 2% trifluoroacetic acid in 20% acetonitrile.
To ensure an even suspension of peptides, the samples
were briefly vortexed and sonicated.
Label-free LC-MS/MS analysis
The nano LC-MS/MS analysis of no bone disease versus
high bone disease patient samples was carried out with
the help of an Ultimate 3000 nanoLC system (Dionex)
coupled to a an LTQ Orbitrap XL mass spectrometrer
(Thermo Fisher Scientific, Dublin, Ireland) in the Pro-
teomics Facility of the National Institute for Cellular
Biotechnology, Dublin City University. The optimized
methodology has been as previously described in detail.
Peptide mixtures (5 μL volume) were loaded onto a
C18 trap column (C18 PepMap, 300 μm id ×5 mm,
5 μm particle size, 100 Å pore size; Dionex). Desalting
was achieved at a flow rate of 25 μL/min in 0.1% TFA
for 10 min. The trap column was switched on-line with
an analytical PepMap C18 column (75 μm id ×500 mm,
3 μm particle and 100 Å pore size; Dionex). Peptides
generated from muscle proteins were eluted with the
following binary gradients: solvent A (2% ACN and
0.1% formic acid in LC-MS grade water) and 0–25%
solvent B (80% ACN and 0.08% formic acid in LC-MS
grade water) for 240 min and 25–50% solvent B for a fur-
ther 60 min. The column flow rate was set to 350 nL/min.
Data was acquired with Xcalibur software, version 2.0.7
(Thermo Fisher Scientific). The MS apparatus was oper-
ated in data-dependent mode and externally calibrated.
Survey MS scans were acquired in the Orbitrap in the
300–2000 m/z range with the resolution set to a value of
30 000 at m/z 400 and lock mass set to 445.120025 u. CID
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the three most intense ions per scan. Within 60 sec, a
dynamic exclusion window was applied. Normalised
collision energy of 35%, an isolation window of 3 m/z
and one microscan were used to collect suitable tandem
mass spectra.
Quantitative profiling by label-free LC-MS/MS analysis
Processing of the raw data generated from LC-MS/MS
analysis was carried out with Progenesis label-free LC-MS
software (version 3.1; Non-Linear Dynamics, Newcastle
upon Tyne, UK). Data alignment was based on the LC
retention time of each sample, allowing for any drift in re-
tention time given and adjusted retention time for all runs
in the analysis. A reference run was established with the
sample run that yielded most features (i.e. peptide ions).
The retention times of all of the other runs were aligned
to this reference run and peak intensities were then
normalised. Prior to exporting the MS/MS output files to
MASCOT (http://www.matrixscience.com) for protein
identification, a number of criteria were employed to filter
the data including: (i) peptide features with ANOVA <0.05
between experimental groups, (ii) mass peaks (features)
with charge states from +2, +3, and (iii) greater than one
isotope per peptide. A MASCOT generic file was gener-
ated from all exported MS/MS spectra from Progenesis
software. The MASCOT generic file was used for peptide
identification with MASCOT (version 2.2) and searched
against the UniProtKB-SwissProt database (downloaded in
January 2013) with 16,638 proteins (taxonomy: Homo
sapiens). The following search parameters were used for
protein identification: (i) MS/MS mass tolerance set at 0.5
Da, (ii) peptide mass tolerance set to 20 ppm, (iii) carba-
midomethylation set as a fixed modification, (iv) up to
two missed cleavages were allowed and (v) methionine oxi-
dation set as a variable modification. For further consider-
ation and re-importation back into Progenesis LC-MS
software for further analysis, only peptides with ion scores
of 40 and above were chosen. Importantly, the following
criteria were applied to assign a serum associated proteins
as properly identified: (i) an ANOVA score between experi-
mental groups of ≤0.05, (ii) proteins with ≥2p e p t i d e s
matched and (iii) a MASCOTscore >40.
Enzyme-linked immunosorbent assay
Serum samples were screened using different enzyme-
linked immunosorbent assays for Human Complement C4
ELISA Kit (EC2102-1, Assaypro), Human Apolipoprotein B
(EA7001-1, Assaypro) and Human Paraoxonase 1 (PON1)
(SK00141-01, Aviscera Bioscience, Inc). Both Apo B100
and PON1 were assayed using a quantitative sandwich
enzyme immunoassay technique, while C4 was measured
using a quantitative competitive enzyme immunoassay
technique.
Statistical analysis
Proteins were considered to be differentially expressed
upon an observation of a fold change of ≥1.4 in both di-
rections and a Benjamini-Hochberg adjusted p-value used
with all proteins ≤0.05 selected. ELISA data was analysed
by constructing a standard curve as a result of plotting the
mean absorbance for each standard on the x-axis against
the concentration on the y-axis and draw a best fit curve
through the points on the graph. Any outliers present in
ELISA readings (*) were determined using Tukey’sm e t h o d
which considers values at a distance of 1.5 times the inter-
quartile range (IQR) below Q1 (quartile one) or at 1.5
times the IQR above Q3 (quartile three). The ROC plots
were obtained by plotting all sensitivity values (true posi-
tive fraction) on the y-axis against their equivalent (1-
specificity) values (false positive fraction) for all available
thresholds on the x-axis (MedCalc, version 13-0-0-0
64-bit, Medcalc Software, Mariakerke, Belgium). The area
under the curve (AUC) was calculated to provide a sum-
mary of overall classifier effectiveness. For multivariate
analysis of biomarker combinations, logistic regression
(LR) analysis of the serum biomarker levels in these
patients groups was performed.
Additional file
Additional file 1: Table S1. Proteomics Data for Responders v
Non-Responders to Bortezomib and Thalidomide.
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